NASDAQ:ORGO Organogenesis Q3 2026 Earnings Date & Estimates $1.29 +0.01 (+0.78%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$1.29 0.00 (0.00%) As of 10/9/2026 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Organogenesis is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for 5:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 5, 2026TimeBefore Market OpensConference Call5:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Organogenesis in Q3 2026Organogenesis is expected to post earnings of -$0.1775 per share on revenue of $52.09 million. In the same quarter a year earlier Organogenesis reported $0.18 per share on revenue of $150.86 million. Organogenesis last reported on August 6, 2026, posting -$0.71 per share and missing the -$0.35 consensus estimate. Organogenesis has beaten the consensus EPS estimate in 3 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.1775Expected Revenue$52.09 millionPrior-Year EPS$0.18Prior-Year Revenue$150.86 millionExpected EPS Growth-198.6%Expected Revenue Growth-65.5%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.71 (Missed by -$0.36)Last Quarter Revenue$43.76 millionEPS Beat Rate3 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Organogenesis Q3 2026 Earnings FAQ When does Organogenesis report Q3 2026 earnings? Organogenesis (NASDAQ:ORGO) is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. What time is Organogenesis' Q3 2026 earnings call? Organogenesis' Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 5:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Organogenesis? Analysts expect Organogenesis to post earnings of -$0.1775 per share for Q3 2026. How much revenue is Organogenesis expected to report? The consensus revenue estimate for Organogenesis is $52.09 million for Q3 2026. Organogenesis Earnings HeadlinesOrganogenesis (ORGO) Q2 2026 Earnings Call TranscriptAugust 13, 2026 | finance.yahoo.comOrganogenesis forecasts 2026 revenue of $179M-$215M amid June restructuring expected to cut $18M annuallyAugust 8, 2026 | seekingalpha.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.October 11 at 1:00 AM | Porter & Company (Ad)Organogenesis Holdings Inc. (ORGO) Q2 2026 Earnings Call TranscriptAugust 7, 2026 | seekingalpha.comOrganogenesis Launches New $75 Million At-The-Market OfferingAugust 6, 2026 | tipranks.comOrganogenesis Holdings Inc. Reports Second Quarter 2026 Financial ResultsAugust 6, 2026 | globenewswire.comSee More Organogenesis Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Organogenesis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Organogenesis and other key companies, straight to your email. Email Address About OrganogenesisOrganogenesis (NASDAQ:ORGO) Holdings Inc. (NASDAQ: ORGO) is a regenerative medicine company that develops, manufactures and commercializes advanced products designed to help repair and restore damaged tissue. Its principal business areas are advanced wound care and surgical and sports medicine, with products intended for use by hospitals, wound-care centers, physicians and other health care providers. The company’s advanced wound-care portfolio includes Apligraf, a living cellular skin substitute used in the treatment of certain chronic wounds, as well as Dermagraft, PuraPly and other biologic and synthetic products. These offerings are designed to support wound closure, tissue regeneration and infection management in conditions such as diabetic foot ulcers, venous leg ulcers and other complex wounds. Organogenesis also provides products for surgical, orthopedic and sports-medicine applications, including biologic matrices and tissue-repair solutions used in procedures involving soft tissue and other musculoskeletal structures. The company was founded in 1985 and is headquartered in Canton, Massachusetts. Its products are marketed primarily in the United States through health care providers and specialized sales channels.View Organogenesis ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
